HighField Biopharmaceuticals Corporation
6 clinical trials · Sponsor
◉ Watch HighField Biopharmaceuticals Corporation
| Record | Firm | Date |
|---|---|---|
| Safety and Activity of HF50 in Patients With Advanced Solid Tumors (NCT07601334) | HighField Biopharmaceuticals Corporation | 2026-06-30 |
| A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma (NCT07678684) | HighField Biopharmaceuticals Corporation | 2026-06-30 |
| HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors (NCT06822998) | HighField Biopharmaceuticals Corporation | 2025-06-11 |
| HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors (NCT05861895) | HighField Biopharmaceuticals Corporation | 2023-12-12 |
| Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors (NCT05388487) | HighField Biopharmaceuticals Corporation | 2022-02-16 |
| Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers (NCT05386823) | HighField Biopharmaceuticals Corporation | 2021-03-20 |
Track HighField Biopharmaceuticals Corporation automatically
Every clearance here is in the API, with alerts when new ones post.